world
US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
South China Morning Post
October 7, 2026
via South China Morning PostYou're reading one story from Newsaly
Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.
A World Of News, One Window.
Explore Today's News
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas. New York-listed ArriVent closed down nearly 47 per cent on Tuesday
Read the full story
Explore More On Newsaly
Voices (0)
Share a 15-second voice reaction. Voices automatically disappear after 10 days.
Sign in to record a voice on this article.
Be the first to share a voice on this article.